Cost-effectiveness analysis of pancreatic enzyme replacement therapy in patients with pancreatic exocrine insufficiency in China

Figure 1 Decision analytic Markov model of pancreatic enzyme replacement therapy compared with no pancreatic enzyme replacement therapy. PERT: Pancreatic enzyme replacement therapy; PEI: Pancreatic exocrine insufficiency.

Figure 2 Health state transition diagram. PEI: Pancreatic exocrine insufficiency.

Figure 3 One-way sensitivity analyses. A: Scenario 1 (unresectable pancreatic cancer); B: Scenario 2 (pancreatic cancer post-surgery); C: Scenario 3 (chronic pancreatitis after endoscopic treatment). PC: Pancreatic cancer, CP: Chronic pancreatitis; PERT: Pancreatic enzyme replacement therapy; ICER: Incremental cost-effectiveness ratio.

Figure 4 Probabilistic sensitivity analyses. USD: United States dollar.

Figure 5  Cost-effectiveness acceptability curves.